Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rank in Stocks #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Share Price
$0.11725176
Last synced: 2025-07-14
Market Cap
$481.50K
Change (1 day)
-0.20%
Change (1 year)
0.00%
Country
FR
Trade PHAXIAM Therapeutics S.A. (PHXM)

Category

EPS for PHAXIAM Therapeutics S.A. (PHXM)
EPS as of June 2024 TTM: $-4.23
According to PHAXIAM Therapeutics S.A. latest financial reports and stock price the company's current EPS (TTM) is $-4.23. At the end of 2022 the company had a EPS of $-0.07 a decrease compared to its 2021 EPS that were of $-23.87.
EPS history for PHAXIAM Therapeutics S.A. from 2016 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-4.23 -23.50%
2023 $-5.53 7,492.45%
2022 $-0.07 -99.69%
2021 $-23.87 -46.82%
2020 $-44.88 23.87%
2019 $-36.23 60.03%
2018 $-22.64 -30.76%
2017 $-32.70 21.96%
2016 $-26.81 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -509.44%
US
$27.74 -755.76%
NL
- -
CH
- -
KR
$13.70 -423.86%
BE